LB Pharmaceuticals (LBRX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

LBRX · Stock Price

USD 31.98+14.68 (+84.86%)

Market Cap: $941.3M

Historical price data

Overview

LB Pharmaceuticals (NASDAQ: LBRX) is a clinical-stage biotech company founded in 2019 with a mission to develop novel therapies for severe neuropsychiatric disorders. Its core strategy centers on the rational optimization of amisulpride to create LB-102, a potential first-in-class benzamide antipsychotic for the U.S. market, aiming to reduce development risk while pursuing meaningful clinical differentiation. The company has advanced LB-102 into Phase 2 clinical trials, assembled a leadership team with deep neuropsychiatric expertise, and is backed by a board with significant biotech and venture capital experience.

SchizophreniaBipolar DepressionNeuropsychiatric Diseases

Technology Platform

Rational chemical optimization platform focused on benzamide antipsychotics, specifically designing modified compounds like LB-102 (a methylated derivative of amisulpride) to enhance blood-brain barrier penetration and optimize the dopamine D2/D3 receptor selectivity profile for improved efficacy and tolerability.

Opportunities

LB-102 addresses multi-billion dollar markets in schizophrenia and bipolar depression with high unmet need for better-tolerated therapies.

Its strategy as a potential first-in-class (U.S.) benzamide antipsychotic leverages decades of ex-U.S.

safety data, offering a de-risked development path and a clear differentiation story based on a unique receptor profile and potentially improved side-effect burden.

Risk Factors

The company faces high clinical and regulatory risk as LB-102 must prove itself in FDA trials for a novel drug class in the U.S.

It also carries extreme pipeline concentration risk, with its entire valuation tied to a single asset, and will face intense commercial competition from low-cost generics and established branded antipsychotics upon any potential launch.

Competitive Landscape

LB-102 competes in the crowded antipsychotic market dominated by generic and branded atypical antipsychotics. Its primary competition will be newer branded agents promoting differentiated profiles (e.g., lumateperone, cariprazine). LB-102's key differentiator is its benzamide-class heritage, offering a potential alternative with a distinct receptor selectivity profile aimed at minimizing metabolic and motor side effects.

More companies in Small Molecule Drugs →More companies in United States →